Docetaxel for Metastatic Hormone-sensitive Prostate Cancer: Urgent Need to Minimize the Risk of Neutropenic Fever

Che Kai Tsao; Matthew D. Galsky; William K. Oh

doi:10.1016/j.eururo.2016.06.041

Docetaxel for Metastatic Hormone-sensitive Prostate Cancer: Urgent Need to Minimize the Risk of Neutropenic Fever

Che Kai Tsao, Matthew D. Galsky, William K. Oh

Research output: Contribution to journal › Editorial

16 Scopus citations

Abstract

First-line docetaxel treatment for metastatic castration-sensitive prostate cancer is associated with higher rates of neutropenic fever compared with those with castration-resistant disease, and prophylactic granulocyte colony-stimulating factor should be considered in those harboring risk factors for developing neutropenia.

Original language	English
Pages (from-to)	707-708
Number of pages	2
Journal	European Urology
Volume	70
Issue number	5
DOIs	https://doi.org/10.1016/j.eururo.2016.06.041
State	Published - 2016

Access to Document

10.1016/j.eururo.2016.06.041

Cite this

@article{07401df3e7d647f4b75c9951ac421547,

title = "Docetaxel for Metastatic Hormone-sensitive Prostate Cancer: Urgent Need to Minimize the Risk of Neutropenic Fever",

abstract = "First-line docetaxel treatment for metastatic castration-sensitive prostate cancer is associated with higher rates of neutropenic fever compared with those with castration-resistant disease, and prophylactic granulocyte colony-stimulating factor should be considered in those harboring risk factors for developing neutropenia.",

author = "Tsao, {Che Kai} and Galsky, {Matthew D.} and Oh, {William K.}",

note = "Publisher Copyright: {\textcopyright} 2016 European Association of Urology",

year = "2016",

doi = "10.1016/j.eururo.2016.06.041",

language = "English",

volume = "70",

pages = "707--708",

journal = "European Urology",

issn = "0302-2838",

publisher = "Elsevier B.V.",

number = "5",

}

TY - JOUR

T1 - Docetaxel for Metastatic Hormone-sensitive Prostate Cancer

T2 - Urgent Need to Minimize the Risk of Neutropenic Fever

AU - Tsao, Che Kai

AU - Galsky, Matthew D.

AU - Oh, William K.

PY - 2016

Y1 - 2016

N2 - First-line docetaxel treatment for metastatic castration-sensitive prostate cancer is associated with higher rates of neutropenic fever compared with those with castration-resistant disease, and prophylactic granulocyte colony-stimulating factor should be considered in those harboring risk factors for developing neutropenia.

AB - First-line docetaxel treatment for metastatic castration-sensitive prostate cancer is associated with higher rates of neutropenic fever compared with those with castration-resistant disease, and prophylactic granulocyte colony-stimulating factor should be considered in those harboring risk factors for developing neutropenia.

UR - http://www.scopus.com/inward/record.url?scp=84996528058&partnerID=8YFLogxK

U2 - 10.1016/j.eururo.2016.06.041

DO - 10.1016/j.eururo.2016.06.041

M3 - Editorial

C2 - 27417033

AN - SCOPUS:84996528058

SN - 0302-2838

VL - 70

SP - 707

EP - 708

JO - European Urology

JF - European Urology

IS - 5

ER -

Docetaxel for Metastatic Hormone-sensitive Prostate Cancer: Urgent Need to Minimize the Risk of Neutropenic Fever

Abstract

Access to Document

Fingerprint

Cite this